Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6582727 | EIRGEN | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
Aug, 2020
(3 years ago) | |
US8906410 | EIRGEN | Oral dosage form of 25-hydroxyvitamin D |
Feb, 2027
(2 years from now) | |
US9943530 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Feb, 2027
(2 years from now) | |
US10213442 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Feb, 2027
(2 years from now) | |
US9925147 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(3 years from now) | |
US8778373 | EIRGEN | Methods for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(3 years from now) | |
US9408858 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(3 years from now) | |
US8207149 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(3 years from now) | |
US9498486 | EIRGEN | Method for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(3 years from now) | |
US11154509 | EIRGEN | Methods for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(3 years from now) | |
US8361488 | EIRGEN | Methods and compositions for controlled release oral dosage of a vitamin D compound |
Jul, 2028
(4 years from now) | |
US8426391 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Aug, 2028
(4 years from now) | |
US11801253 | EIRGEN | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
Sep, 2030
(6 years from now) | |
US11253528 | EIRGEN | Stabilized modified release Vitamin D formulation and method of administering same |
Mar, 2034
(9 years from now) | |
US9861644 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(9 years from now) | |
US10300078 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(9 years from now) | |
US10357502 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(9 years from now) |
Rayaldee is owned by Eirgen.
Rayaldee contains Calcifediol.
Rayaldee has a total of 17 drug patents out of which 1 drug patent has expired.
Expired drug patents of Rayaldee are:
Rayaldee was authorised for market use on 17 June, 2016.
Rayaldee is available in capsule, extended release;oral dosage forms.
Rayaldee can be used as use of sustained or extended release oral 25-hydroxyvitamin d3 in treating secondary hyperparathroidism in adult patients having chronic kidney disease stage 3 or 4, use of sustained release 25-hydroxyvitamin d in treating patients having 25-hydroxyvitamin d insufficiency or deficiency, use of controlled release 25-hydroxyvitamin d in treating secondary hyperparathyroidism in patients having chronic kidney disease, treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease using controlled release, oral 25-hydroxyvitamin d, treating secondary hyperparathyroidism in stage 3 or 4 ckd with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level while avoiding pth oversuppression, treating secondary hyperparathyroidism in ckd with sustained release calcifediol to reduce the patient's serum parathyroid hormone level and tmax is increased compared to bolus iv injection and immediate-release, oral dosing, treatment of secondary hyperparathyroidism with sustained release 25-hydroxyvitamin d in chronic kidney disease patients receiving cyp3a inhibitors, maintaining serum 25-hydroxyvitamin d at a level of at least 30 ng/ml with oral, sustained release 25-hydroxyvitamin d, administration of 25-hydroxyvitamin d3 by controlled release.
The generics of Rayaldee are possible to be released after 14 March, 2034.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jun 17, 2019 |
Drugs and Companies using CALCIFEDIOL ingredient
Market Authorisation Date: 17 June, 2016
Treatment: Maintaining serum 25-hydroxyvitamin d at a level of at least 30 ng/ml with oral, sustained release 25-hydroxyvitamin d; Treating secondary hyperparathyroidism in ckd with sustained release calcifediol...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL